Hospice care and palliative medicine focus on relieving a patient's physical symptoms and helps patients and their families with their spiritual and mental health needs. San Diego Hospice and The Institute for Palliative Medicine is the only hospice and palliative care provider in the nation with a full-time palliative care psychiatry program. Its work with ketamine is one of the many clinical trials that the nonprofit organization has conducted.
 
'Our goal at San Diego Hospice and The Institute for Palliative Medicine is to prevent and relieve suffering and promote quality of life,' noted Dr. Irwin. 'Standard antidepressants do not work often enough or fast enough for relieving the tremendous suffering associated with depression for patients. Ketamine promises to work better and faster, allowing us to achieve this goal.'
 
About San Diego Hospice and The Institute for Palliative Medicine
San Diego Hospice and The Institute for Palliative Medicine is one of the largest community-owned, nonprofit hospices in the country, and considered the only academic hospice program in the region. San Diego Hospice brings compassionate, expert medical care to nearly 1,200 seriously ill adults and children each day throughout the county. More information is available online at www.sdhospice.org or call toll-free: 1-866-688-1600. Join our online communities on Facebook, Twitter,  YouTube and Google+.

— WebWireID152319 —

What are electronic health records, you may ask? Electronic health records are a digital copy of a patient's medical history, including known allergies, demographics, immunization records, laboratory results, radiology images, vital signs, age, weight and billing information. Storing health records in this way helps to reduce cost by saving paper.

Aspire Medical Solutions also offers a broad range of equipment and testing. One example of the types of testing and equipment they offer is the VAT-ENG for dizziness, vertigo, and fall prevention. The ​​VAT-ENG is similar to the VNG equipment but clinically more significant.

This equipment is used when testing for vertigo. This vertigo testing equipment is a must have for any Internal Medicine, Family Practice, and Ear, Nose & Throat Specialist.

Check out the following web page at http://www.aspiremed.org/care-and-profit-analysis/ to learn more about how Aspire Medical Records can help your practice.

— WebWireID152258 —

— WebWireID152098 —

Reaxys Xcelerate™ has been designed to streamline research intensive chemistry workflows for:

- Synthetic chemists who need to view and analyze numerous potential retrosynthetic pathways can get immediate, automated, multiple synthetic plans, complete with access to the necessary background data, ensuring they can make informed decisions about the most effective routes to take to the lab.
- Chemistry researchers who need to compare and contrast multiple datasets can utilize Reaxys Xcelerate's intelligent results visualization, reducing data analysis complexity. Context sensitive graphical overviews and the ability to cluster results for maximum relevance enables immediate insights, which speeds up the analysis process.
- Global teams and diverse research groups who need to share information across labs and geographies can use enhanced information exchange capabilities. Researchers can pinpoint the exact area of interest, annotate with further insights or instructions and share instantly with colleagues for more effective teamwork.

'Working closely with our partners, we identified and invested in a number of new tools to support research intensive workflows,' said Mark van Mierle, Managing Director of Elsevier's Pharma and Biotech Group. 'For organizations in competitive research environments, whether at corporations developing new materials, pharmaceutical organizations developing potential drugs, or academic institutions conducting groundbreaking research Reaxys Xcelerate™ provides a step change in individual and organizational productivity.'

Reaxys ® and Reaxys Xcelerate™ follow the same agile development process, ensuring that the two versions continue to deliver the relevant content and insights needed by research chemists. To find out more about Reaxys Xcelerate™, including the opportunity to experience the product, visit www.reaxys.com/info/xcelerate.

Reaxys ® and the Reaxys trademark are owned and protected by Elsevier Properties SA and used under license.

# # #

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

— WebWireID152127 —

The human-to-human transmission of new, highly pathogenic strains of influenza virus poses today a major threat to human health and to the security of global society. With its rapid global spread, the 2009 pandemic (pdm) influenza virus reminded the world of this threat, resulting in an estimated 18,000 deaths worldwide. In Japan, infected patients over the winter season of 2009 accounted for a staggering 16% of the total population.

Tackling the challenge of such global pandemics requires new technology for rapid clinical diagnosis. To answer this need, Toshihisa Ishikawa and colleagues at the RIKEN OSC developed the RT-SmartAmp assay, a technique to rapidly detect the 2009 pdm influenza A(H1N1) virus from patient swab samples. By combining both reverse transcriptase (RT) and isothermal DNA amplification reactions in one step, the RT-SmartAmp assay does away with the need for RNA extraction and PCR reaction. The researchers adapted the RT-SmartAmp technique using a fluorescent primer to specifically detect the 2009 pdm influenza A(H1N1) virus within 40 minutes, without cross-reacting with the seasonal A(H1N1), A(H3N2), or B-type (Victoria) viruses.

The effectiveness of the RT-SmartAmp method was confirmed in clinical research carried out at Japanese hospitals during the period of October 2009 to January 2010, where it outperformed standard diagnosis tests in both speed and sensitivity. Of a total 255 clinical samples, 140 (54.9%) were identified as 2009 pdm A(H1N1)-positive by RT-SmartAmp, compared to only 110 (43.1%) detected by standard diagnostic tests. In 72.8% of all 140 infection-positive cases, the RT-SmartAmp assay detected the presence of the pdm influenza virus within 24 hours of fever onset.

Taken together, these results set a new standard for infection diagnosis speed, providing a highly-effective tool for rapidly detecting sub-types of the H5N1 virus and oseltamivir-resistant influenza viruses and promising support in the battle to prevent global pandemic infection.

Reference:

Yuki Kawai, Yasumasa Kimura, Alexander Lezhava, Hajime Kanamori, Kengo Usui, Takeshi Hanami, Takahiro Soma, Jean-Etienne Morlighem, Satomi Saga, Yuri Ishizu, Shintaro Aoki, Ryuta Endo, Atsuko Oguchi-Katayama, Yasushi Kogo, Yasumasa Mitani Takefumi Ishidao, Chiharu Kawakami, Hideshi Kurata, Yumiko Furuya, Takayuki Saito, Norio Okazaki, Masatsugu Chikahira, Eiji Hayashi, Sei-ichi Tsuruoka, Tokumichi Toguchi, Yoshitomo Saito, Toshiaki Ban, Shinyu Izumi, Hideko Uryu, Koichiro Kudo, Yuko Sakai-Tagawa, Yoshihiro Kawaoka, Aizan Hirai, Yoshihide Hayashizaki, and Toshihisa Ishikawa. "One-step detection of the 2009 pandemic influenza A(H1N1) virus by the RT-SmartAmp assay and its clinical validation". PLoS ONE, 2012, doi:10.1371/journal.pone.0030236

About RIKEN

RIKEN is Japan's flagship research institute devoted to basic and applied research. Over 2500 papers by RIKEN researchers are published every year in reputable scientific and technical journals, covering topics ranging across a broad spectrum of disciplines including physics, chemistry, biology, medical science and engineering. RIKEN's advanced research environment and strong emphasis on interdisciplinary collaboration has earned itself an unparalleled reputation for scientific excellence in Japan and around the world.

About the Omics Science Center

Omics is the comprehensive study of molecules in living organisms. The complete sequencing of genomes (the complete set of genes in an organism) has enabled rapid developments in the collection and analysis of various types of comprehensive molecular data such as transcriptomes (the complete set of gene expression data) and proteomes (the complete set of intracellular proteins). Fundamental omics research aims to link these omics data to molecular networks and pathways in order to advance the understanding of biological phenomena as systems at the molecular level.

Here at the RIKEN Omics Science Center, we are developing a versatile analysis system, called the "Life Science Accelerator (LSA)", with the objective of advancing omics research. LSA is a multi-purpose, large-scale analysis system that rapidly analyzes molecular networks. It collects various genome-wide data at high throughput from cells and other biological materials, comprehensively analyzes experimental data, and thereby aims to elucidate the molecular networks of the sample. The term "accelerator" was chosen to emphasize the strong supporting role that this system will play in supporting and accelerating life science research worldwide.

— WebWireID152022 —

NICE has recommended the Discovery CT750 HD scanner as an option both for first line cardiac imaging of the coronary arteries in people with suspected coronary artery disease (CAD) – and for evaluating known CAD patients' disease progression to establish the necessity for revascularization (an augmented blood supply) - in people deemed difficult to image using earlier generation CT scanners.

CAD, which in 2007 was estimated to have caused 91,000 deaths in the UK, is characterized by the narrowing of the coronary artery leading to a reduction in blood flow to the heart, and angina. NICE's recent clinical guideline on chest pain (CG95) cites an estimated 2.6 million people in the UK with CAD. Additionally it is estimated that one per cent of the general population consults their General Practitioner (GP) with chest pain.

Historically, factors including patient obesity, high levels of coronary calcium, high heart rates of over 65 beats per minute, the presence of stents (tubes placed in the coronary arteries to keep them open in the treatment of CAD) or arrhythmias (problems with the rate or rhythm of a heartbeat) have caused difficulties in imaging patients with earlier generation CT scanners.

However, the latest technology in new generation scanners helps overcome these difficulties, and allows high quality images to be acquired faster and with a reduced radiation dose, which can mean less exposure and less time in a scanner for patients.

The NICE recommendation paves the way for reliably ruling out significant stenosis (the narrowing of a blood vessel) in 'difficult to image' patients, avoiding the need for uncomfortable and more costly investigations such as invasive coronary angiography (ICA).

At the end of 2010 the National Audit Office (NAO) recorded 426 NHS CT scanners in England, of which 376 were installed in the last ten years. Of the current scanners in use only 40 are new generation. With NAO estimating that 50% of all NHS CT scanners will need replacing in the next three years, and that number rising to 80% within six years, many local service providers and commissioners will now be considering the prevalence in their local populations of cardiac patients who fall into this 'difficult to image' category.

Professor Carole Longson, Director for NICE's Health Technology Evaluation Centre says: 'We recommend that when selecting CT scanners as part of their medium term asset planning, service providers, working with commissioners and cardiac networks, take into account the benefits outlined in our guidance of access to new generation cardiac CT scanners.'

To date no assessment in NICE's Diagnostic Assessment Programme has resulted in a fully positive recommendation, primarily falling short due to the challenges that diagnostics face in demonstrating clinical and cost effectiveness compared with the more direct evidence generated by pharmacological treatments.

Geoff Wilson who leads the European Health Economics team at GE Healthcare said: 'We are fully behind evidence based medicine. NICE guidance offers the NHS independently assessed evidence helping commissioners identify more innovative, clinically effective and cost effective medical technologies for their clinicians. The GE Discovery CT750 HD was introduced in 2008 as the world's first high definition CT system. The improved resolution makes a big difference in 'difficult to image' patients. The NICE guidance demonstrates there are financial savings to be made by the NHS using new generation scanners for cardiac imaging in these patients. Moreover following the guidance can lead to improved patient care, often eliminating the need for unnecessary investigations.'

In a cardiac CT exam spatial resolution directly translates into accurate, clear images, giving the physician data to help correctly establish the extent of CAD in those who have it, while clearing those without it.

The Discovery CT750HD's industry leading cardiac CT spatial resolution of 18.2lp/cm enables reduced calcium blooming, improved stent visualization and helps accurately quantify stenosis in coronary vessels.

Dr Stephen Harden, Consultant Cardio-Thoracic Radiologist, Southampton General Hospital, says: 'This is an important guidance which will have a positive impact on the practice and growth of cardiac CT. It demonstrates that cardiac CT is an established, clinically useful technique which, according to current evidence, can be used even with difficult to image patients. It is likely that more cardiac CT scans will be performed because of increasing referrer confidence in the technique. It is also likely that this increased demand will encourage more units to consider starting their own cardiac CT programme.'

###

ABOUT GE HEALTHCARE
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our 'healthymagination' vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

For our latest news, please visit http://newsroom.gehealthcare.com.

— WebWireID151989 —

Founded in 2009, Versartis initially occupied contract office space that included basic phone service. Additional services, like teleconferencing, were sourced by third-party vendors. When the company landed at their next location as tenants later that year, they needed communication equipment and service for the four full-time employees. A primary requirement was that the system had to accommodate the anticipated growth of the company.

'We needed a phone system that was stable, cost-effective and provided good phone and handset performance in terms of features as well as clarity,' said CEO and Founder Jeff Cleland. 'When we called in the phone company, it made us re-think spending such a significant amount for traditional phone service, so we sought alternatives.'

That's when a colleague suggested United Data Voice, a Northern California telecommunications provider that specializes in start-ups and small business.

'As a growing company, we needed the usual basic features: access to an intercom, the ability to easily dial out internationally, and presence management. Conference calls are really important for us, and the true value we've extracted is the ad hoc teleconference capability. If we need to set up a conference call on the fly, the Allworx system makes it very easy.'

United Data Voice owner Sean Finney recommended the Allworx 24x combined with PRI (Primary Rate Interface) service from TelePacific. PRI provides up to 23 simultaneous phone lines at an affordable price. Finney said this allows his customer to take advantage of the four conference bridges built in to the Allworx system to host their own teleconferences. 'People using teleconferencing and presence management often can't take full advantage of their systems because of the lack of available phone lines,' Finney said. 'With PRI and Allworx, Versartis doesn't have that problem.'

With any telecommunication system, end-user training is critical to getting the most from its features. Upon initial installation United Data Voice provided a thorough overview of the phone system to all the users, easily referenced desktop materials and specialized training, as needed, for individual users. United Data Voice continues to train new users as they are added.

The company has grown to 11 employees, plus on-site consultants, which necessitated a move to a third location. 'United Data Voice did an excellent job when we transitioned to this facility,' Cleland said. 'They were very diligent about minimizing service interruption in our move, and the phone system in particular has lived up to the promise of its features with exceptional call clarity.'

About United Data Voice
United Data Voice is Northern California's premier provider of powerful, reliable voice and data products for businesses large or small. Our certified professionals have in-depth knowledge and experience installing, servicing and maintaining stand-alone and multi-networked systems. Call United Data Voice for VoIP and traditional telephony, PBX and key systems, call center support, and integrated messaging and collaboration. Visit uniteddatavoice.com to learn more.

— WebWireID151959 —

For the past year, proponents of the European Union's medical device approval process - which allows complex devices to reach consumers in European markets an average of two years sooner than in the U.S. - have been calling for the FDA to adopt a similar process, according to the article. Medical device industry supporters argue that the EU is luring device manufacturers away from the U.S., and contributing to high unemployment rates.

The breast implant debacle in Europe, which involves the removal of thousands of potentially faulty implants manufactured by the now-defunct French company Poly Implants Protheses SA, has brought negative attention to the EU's medical device approval process, however. The European breast implant problem therefore should make U.S. regulators realize that it would be unwise to adopt a medical device approval process similar to the one in Europe, according to Carl Heneghan, an Oxford University teacher who has studied device recalls and is quoted in the Bloomberg article.

'All industry guys in the U.S. say, 'we should have access to these products much sooner, like in Europe,'' the Bloomberg article quotes Heneghan as saying. 'The flip side is, the European people are being used as guinea pigs.'

The importance of subjecting medical devices to comprehensive FDA reviews before they are approved for sale has been highlighted in recent months by the thousands of women in the U.S. who have suffered injuries as a result of vaginal mesh implants. The implants were granted FDA approval based on their similarity to devices already on the market, without the benefit of human testing. The implants have so far spawned more than 650 lawsuits filed by patients alleging that they have been significantly injured as a result of having surgical mesh products implanted transvaginally.

Anyone seeking more information about vaginal mesh can visit the Rottenstein Law Group's Vaginal Mesh Lawsuit Information Center. The site has vital information about the dangers of this medical device, along with easy-to-use social media features that allow for easy sharing on sites like Facebook and Twitter. Visitors are also encouraged to link to their own Web sites and blogs in order to spread the word about defective medical products and dangerous drugs.

About the Rottenstein Law Group
The Rottenstein Law Group is a New York-based law firm that represents clients in mass tort actions. The firm was founded by Rochelle Rottenstein, a lawyer with over two decades of experience in compassionate representation of clients in consumer product injury, mass tort, and class action law suits. For more information, please visit their Web site, or call (888) 9-ROT-LAW.

— WebWireID151840 —

— WebWireID151870 —

— WebWireID151839 —

David Rodgers, M.S. Nutrition, founder of Michigan-based Nutrient Balance Center, aims to change all that with a new natural hair loss protocol outlined in the book 'Reloaded: Natural Hair Loss Secrets for Safe, Effective Hair Growth.'

'I definitely envision a major shift,' said Rodgers, 'where just as in weight loss, people will have the tools to re-grow hair naturally, simply by providing their body with nutrients that should have been there in the first place.'

Rodgers, known in the industry as a nutritionist who helps people with hard-to-diagnose conditions such as Chronic Fatigue Syndrome, began losing his own hair a couple years back. 'I am not one to take no for an answer, nor am I one to agree to long-term drug therapy,' Rodgers said. 'I knew a natural solution would be available for hair loss, but I didn't know how difficult it would be to find.'

Rodgers found his solution after scouring the medical literature and determining what he describes as the four main causes of hair loss: nutrient deficiencies, thyroid hormone imbalance, prostate hormone imbalance, and tissue calcification.

'One thing, for example, that people need to pay particular attention to is the types of fat that they eat,' said Rodgers. 'Even if they're trying to be healthy, the majority of dietary fat often comes from meat, dairy, desserts, and salad dressings. None of these fats help your hair, or help you avoid nutrient deficiency.'

Instead, Rodgers recommends daily intake of fat sources such as raw walnuts and sunflower seeds, as well as an optimal amount of omega 3 fish oil.

Those interested in more hair loss tips are invited to a free webinar, titled 'Five Secrets for Natural Hair Re-growth' happening 8:30pm EST on Thursday, January 26, 2012. Required registration is at www.nutrientbalance.com/hairlosswebinar and seats are limited. The 'Reloaded' book is available at www.reloadedhair.com or on Amazon.

— WebWireID151652 —

— WebWireID151606 —

— WebWireID151605 —

The study was led by Joshua Milner, M.D., in the Laboratory of Allergic Diseases at the National Institute of Allergy and Infectious Diseases (NIAID), and Daniel Kastner, M.D., Ph.D., scientific director at the National Human Genome Research Institute (NHGRI). It will appear in the online edition of the New England Journal of Medicine on Jan. 11, 2012.

The mutation discovered occurs in a gene for phospholipase C-gamma2 (PLCG2), an enzyme involved in the activation of immune cells. The investigators have named the condition PLCG2-associated antibody deficiency and immune dysregulation, or PLAID. "Investigating rare diseases gives researchers more clues about how the healthy immune system functions," says NIAID Director Anthony S. Fauci, M.D. "More importantly, identifying the genetic cause of these disorders opens up possibilities for better disease management and potentially a cure for people who may have spent their entire lives debilitated by severe and unexplained symptoms."

The NIH study involved 27 people from three separate families who all suffered from an inherited form of cold urticaria, an allergic disease characterized by the formation of itchy, sometimes painful hives, episodes of fainting and, in certain cases, life-threatening reactions in response to cold temperatures.

Blood sample analysis revealed that many patients produced antibodies to their own cells and tissues (autoantibodies), making them more susceptible to developing autoimmune disease. More than half had a history of recurrent infections, and laboratory tests revealed that most had low levels of infection-fighting antibodies and low numbers and reduced activity of circulating immune B cells — all symptoms of immune deficiency disease. In three cases, patients had common variable immunodeficiency, a disease that requires frequent intravenous infusions of immune globulin to prevent severe infections. Seven patients suffered from granulomas, inflamed masses of tissue, which formed on their fingers, ears, nose and other parts of their skin.

"This is one of few examples in which the allergy symptom directed us to a genetic syndrome," says Dr. Milner. "In trying to understand the link between this group of conditions — autoimmunity, chronic infections and cold urticaria—we not only identified a disease-causing mutation but uncovered a unique and fascinating genetic mechanism at the crux of allergy, immune defense and self-tolerance."
"This study illustrates the power of multidisciplinary teamwork involving clinicians, geneticists and basic immunologists to get to the heart of seemingly insoluble medical mysteries," says Dr. Kastner. "Our team and colleagues working in the field now have much better odds of improving health outcomes for people with PLAID and for understanding this gene's role in other disorders."

The NIAID investigators teamed up with gene hunting experts in Dr. Kastner's laboratory and found the PLCG2 mutation after performing gene analysis and DNA sequencing studies. The mutation caused the PLCG2 enzyme to function without shutting off. Despite the fact that the enzyme was constantly turned on, immune cells ignored its signaling and did not activate normally.

Investigators performed a series of laboratory experiments to understand how the PLCG2 mutation affects B cells and mast cells, immune cells that contain histamine and other chemicals that are released during an allergic response. Patients' B cells containing the mutated gene fail to turn on normally, leading to their inability to produce antibody, but also an inability to sense when they are producing autoantibodies. Laboratory-developed mast cells containing the mutated gene released chemicals on exposure to cool temperatures, which could explain why the patients developed cold-induced hives.

According to the investigators, their findings suggest that inhibiting PLCG2 activity could be a therapeutic strategy to treat cold-induced hives, autoimmunity and immune deficiency in people with PLAID, but more studies are needed. The study findings also suggest that people previously diagnosed with common variable immunodeficiency disease or with granulomatous diseases could have a PLCG2 gene mutation. Further study is needed to understand PLAID and how mutations in PLCG2 could contribute to other allergic and immunologic disorders.

"These findings are gratifying both for researchers and for people with this disorder," says NHGRI Director Eric Green, M.D., Ph.D. "Furthermore, this study illustrates how genome-analysis methods can empower efforts to unravel the molecular basis of rare genetic diseases."

NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

NHGRI is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases. Additional information about NHGRI can be found at its website, www.genome.gov.

About the National Institutes of Health (NIH):
NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

— WebWireID151476 —

The ARALOC SalesForce product is a mobile content distribution platform that enables any organization to securely distribute content and track all content interaction for sales representatives and field management on mobile devices including; iPhone, iPad and Android.

SalesForce is based on Modevity's industry leading ARALOC™ – Secure Content Distribution & DRM platform that is supporting global leaders in varied market segments.

'In speaking with corporate executives in Sales and Marketing, we understand the vital importance of providing both an easy to use and highly secure system for sales representatives and management to get access to confidential content on mobile devices,' said Thomas J. Canova, Co-Founder, and CMO of Modevity. 'Corporations are increasingly concerned about providing content protection and security to their proprietary sales, product and marketing content that is distributed and viewed on the representative's mobile device such as the iPad', stated Canova.

ARALOC SalesForce is differentiated from other sales portal and e-detail products in that our system provides strong 256bit encryption, mobile content management, secure off-line viewing, along with content annotations and extensive view tracking analytics.  'Globus Medical will be using ARALOC to support both their secure mobile content distribution and content view tracking needs,' added Canova.

Highlights of the ARALOC SalesForce platform include; secure distribution, content annotations with synchronization and versioning, content mobile library that provides for push notification and mobile content management, 256 bit AES encryption, powerful rights management controls, multiple file types – video, audio, MS office, PDF, HTML5, graphic files, real-time feedback response and surveys, and content tracking analytics.

Modevity provides the ARALOC™ Mobile Content Distribution & DRM Platform on completely outsourced software as a service (SaaS) basis to minimize an organization's internal resources and capital expenditures. 
 
About Modevity, LLC:

Modevity founded in 2004 is a leader in content distribution and protection solutions. Our ARALOC™ product solution provide clients with a powerful content distribution and protection platform with extensive content rights management security controls and viewer tracking, reporting and analytics.
Modevity is headquartered in West Chester, PA. 

— WebWireID151442 —

According to Randy Wall, the company representative, this is a product that can be effectively applied to almost any surface, and 'will work for up to 90 days protecting you, your family, co-workers, or your customers from dangerous germs.'

PureShield Inc. is a provider of several unique and cutting edge product technologies for manufacturers, janitorial, hygiene and biological surface protectors, home and business cleaning supplies, and auto care industries.

'This anti-bacterial laundry detergent,' according to Wall, 'is indeed a better solution for protecting persons who are health-conscious, germa-phobic, green product users, and non-toxic product users from having their clothing being infected with bacteria.'

However, he argued that while there are many anti-bacterial laundry soaps on the market, most provide a very short-lived solution.

'Now, with our newly EPA approved product, it provides longer lasting protection for clothing. And we have proof to back it up by providing further details at anti-bacterial laundry solution website and learn about the unique benefits of this anti-microbial laundry treatment,' said Wall. The website also provides a video that clearly explains how Bio Protect 500 can help people in their homes or business places.

With many people being health conscious these days and looking for alternative products to what is being generally provide on the market, PureShield's Bio-Protect 500 laundry detergent 'offers one the best non-toxic solution to reduce the spread of bacteria and mold.'

For further information, please visit http://bio-protect-500.com.

— WebWireID151342 —

— WebWireID151283 —

Ms. Goyke brings nearly 25 years of experience leading technology and business process organizations to top performance with particular expertise in the contact center environment. Ms. Goyke joins Touchpoint after serving as Chief Information Officer and Senior Vice President at ICT Group. During her 10 years at ICT, she was responsible for their 180-person global IT delivery organization supporting a leading call center and business process outsourcer. Prior to ICT, Ms. Goyke was Senior Manager at Ernst and Young where she directed client engagements and revenue production for their high growth unit and call center practice. Moreover, she held executive leadership roles at Electronic Data Systems where she led 8 call centers supporting 2,000 employees.

'Pam brings the technical and strategic expertise, along with the business management background of a successful operations executive,' commented Rick Keefer, President and CEO, Publicis Touchpoint Solutions. 'This strong combination of skills and experience will be an important addition to our executive management team and will support our company-wide efforts to enhance our operational efficiencies in all customer focused relations. We're excited for her to join our team.'

Ms. Goyke will report directly to Rick Keefer and be based out of Touchpoint's headquarters in Yardley, PA. 
 
###
 
For business inquiries, please contact Touchpoint Business Development, at (215) 525-9810 or eMail Impact@TouchpointSolutions.com.
 
About Publicis Touchpoint Solutions, Inc.
Publicis Touchpoint Solutions provides a comprehensive array of multichannel message delivery solutions to the life sciences industry. From in field to inside and from promotional to clinical, Publicis Touchpoint Solutions centers-of-excellence include field sales and service, live video detailing, inside credentialed sales specialists, inside sales and service, clinical health educators, and medical science liaisons. A wide range of vital support solutions—each of which serves all of the company's message delivery channels—includes recruiting, training, performance management, operations, data/analytics, and compliance. Publicis Touchpoint Solutions provides the human touch to precision multichannel messaging delivered at the right time and through the right channels to achieve maximum impact. Publicis Touchpoint Solutions is a member of the Publicis Healthcare Communications Group.

Website:          www.TouchpointSolutions.com
Twitter:            http://twitter.com/pTouchpoint
LinkedIn:         http://linkd.in/pTouchpoint    
 
 
About Publicis Healthcare Communications Group
Publicis Healthcare Communications Group (PHCG) is the largest health-oriented agency network in the world. A division of Publicis Group, PHCG manages top-tier agencies specializing in promoting innovative solutions in advertising, medical education, sales and marketing, digital, market access, and medical and scientific affairs. PHCG is dedicated to delivering ideas of purpose that compel action, change lives, and amplify business outcomes. With more than 4,000 employees, PHCG manages 14 agency brands through 53 offices located in 11 countries. PHCG's global brands are Saatchi & Saatchi Health, Publicis Life Brands, Digitas Health, Razorfish Health, Publicis Healthware International, Publicis Touchpoint Solutions, and Publics Medical Education Group, as well as strong regional brands.

Web: www.publicishealthcare.com | Facebook: www.facebook.com/publicishealthcare
 

— WebWireID151310 —

To register or request additional information, please visit http://www.genesissolutions.com/request-information/

Download the Complete Agenda with Speaker Bios (PDF)

Topics that will be discussed include:

• Maintenance Maturity Continuum
• Current State Assessment
• Maintenance Master Planning
• Implementation Models for Operational Excellence
• Maintenance Excellence Governance Model
• Reliability Based Maintenance
• Maximizing Return on Investment

• Organizational Readiness
• CMMS Functionality & Utilization (IBM Maximo Asset Management, Infor EAM, Oracle EAM, SAP PM)
• MRO Supply Chain
• PM Optimization
• Planning & Scheduling

Instructors: Mike Greenholtz, VP of Reliability Solutions, Joe Pitman, VP of Sales & Marketing, John Rocco, EVP, The Mundy Companies

We hope you can join us for this educational and interactive discussion. Please contact (203) 431-0281 or Register Here

— WebWireID151260 —

Please join HBA for an evening of networking and learning. Kick off the New Year by reconnecting with colleagues and making some new contacts, too. This event is open to both HBA members and nonmembers, but space is limited and online registration closes at midnight on Sunday, January 22. Onsite registration is permitted. To register and/or for more information please visit http://bit.ly/MetroHollywood.
 
###
 
About the HBA
The Healthcare Businesswomen's Association (HBA) is in its fourth decade as a global not-for-profit organization dedicated to furthering the advancement of women in healthcare worldwide. With 15 chapters throughout the US and in Europe, the HBA is headquartered in New Jersey with offices in Philadelphia and Research Triangle Park. The HBA provides educational opportunities for women and men to develop cutting-edge healthcare industry knowledge and leadership skills; recognizes outstanding women and men in the industry; provides opportunities for networking; creates greater visibility for women in the industry; fosters mentoring relationships and serves as a conduit and sponsor for research on career advancement issues. The HBA has over 6,000 individual members and over 130 Corporate Partners. It is widely recognized as the catalyst for leadership development of women in healthcare worldwide and was named by Leadership Excellence as having one of the top leadership development programs in North America for the last four years.
Website: www.HBAnet.org
 
About the HBA Metro Chapter
The HBA Metro Chapter is the founding and largest chapter of the HBA in the heart of the east coast's life sciences corridor, serving members in New York, New Jersey and Connecticut. The HBA Metro Chapter provides a wide variety of leadership development offerings, including Affinity/Special Interest Programs, CONNECTIONS Networking Events, evening Keynote Programs, virtual programs, an annual group mentoring program and special offerings for executive and senior-level women via the chapter's Executive Women's Outreach initiative. A host of volunteer opportunities are available for members who seek to support the chapter and enrich their HBA experience.
Website: www.HBAnet.org/chapter/metro
Facebook: www.facebook.com/HBAmetro    
LinkedIn: http://linkd.in/HBAmetroLI
Twitter: www.twitter.com/HBAnet_metro

— WebWireID151256 —